Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Scandion Oncology
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Proof-of-concept incoming === Scandion Oncology with its lead asset SCO-101 is targeting indications where there exists significant unmet medical need and resistance to chemotherapy is common. Part 2 of Scandion Oncology’s CORIST study in mCRC will report top-line data in mid-2022. The study is investigating the effect of SCO-101 in tumours that have become resistant to treatment with FOLFIRI, representing last-line therapy. Positive results here would represent the first clinical proof-of-concept for SCO-101 and represent a significant near-term catalyst, in Edison Investment Research's view.
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)